A few days ago, Xiangtan held the 2016 annual medical device work conference and the annual meeting of the medical device society. The meeting summarized the supervision of medical equipment in the city in 2015, and reported on some key issues such as insufficient training of some medical equipment enterprises and insufficient quality management, and arranged for the 2016 work. meeting venue In 2016, the Municipal Food and Drug Administration will organize special rectification of denture and active device manufacturers, and actively implement the quality management standards for medical enterprises, consolidate the results of the “four investigations†of medical devices, conduct flight inspections, and continuously eliminate medical devices. Industry quality safety risks and risks. The meeting requested that all member units strengthen their quality and safety awareness, be honest, trustworthy, law-abiding, actively innovate, and promote the healthy development of the medical device industry. A group of advanced units and individuals were commended At the meeting, 17 A-level credit companies, 9 advanced units for adverse event monitoring, and 11 advanced individuals for adverse event monitoring were commended. In China, nervous system drugs are also one of the drugs with the most rapid sales growth in recent years. In 2002, nervous system drugs occupied 5.9% of the entire pharmaceutical market share, and the total sales amount increased by 9.4%. buy nootropics,nootropics benefits,nootropics for adhd,nootropics for weight loss,nootropics supplements Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropic.com
With the increasing trend of urbanization and aging, the elderly population in China has exceeded 120 million, and the incidence of geriatric diseases, especially mental diseases, is increasing year by year. With the increase of residents' income, the elderly's requirements for quality of life also increase. As a result, the demand for drugs to treat mental illnesses such as Alzheimer's has soared. In WHO drug classification, psychotropic drugs and nootropic drugs are grouped into one class. We briefly analyzed the development trend of this class of drugs through the clinical drug use data collected from more than 300 domestic key hospitals by Chinese Pharmaceutical Association.
The overall market size of this class of drugs is about 1.22 billion yuan, the consumption sum increased by 5.0% in 2002, but the sales quantity increased by 11.2%. The main reason why the consumption sum did not increase with the sales quantity is that several main varieties of this class of drugs, such as piracetam, cobalt bin amide and ginkgo biloba leaf, etc. In 2002, the price of selling units fell sharply due to bidding. Among these drugs, ginkgo biloba preparation occupies the largest market share, accounting for more than 1/3 of the market share, ganglioside ester and cobalt bin amide combined also occupy nearly 1/3 of the market share, piracetam and other "sitan" drugs occupy nearly 10% of the market share, the rest of the drugs occupy less than 5% of the market share. At present, more than 20 ginkgo leaf production enterprises, piracetam production enterprises more than 70, have entered the stage of price competition, profit repeatedly diluted.
In the first-line varieties, except ginkgo biloba leaves preparation maintained vigorous vitality, the growth of other varieties were weak, especially the traditional variety piracetam suffered from bidding